Plain-English translation of NCT07044908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called TQB2922 combined with other cancer drugs (including a tablet called TAS-102, and possibly bevacizumab) for people with advanced colorectal cancer that has stopped responding to standard chemotherapy treatments. The study will measure whether this combination is safe and whether it helps slow or stop the cancer from growing.
Many people with advanced colorectal cancer run out of effective treatment options after their cancer stops responding to the standard chemotherapy drugs. This medication is being studied to see if it offers a new hope for patients who have limited choices left.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication through an IV infusion (into your vein) regularly over several weeks, along with taking oral cancer medication tablets on specific days. The study involves multiple visits to the clinic for blood tests, scans, and check-ups to monitor how you are doing and how your cancer is responding. The entire treatment period typically lasts for multiple cycles of 28 days each, continuing as long as the treatment is working and you are tolerating it well.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China